Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 mutant||lung non-small cell carcinoma||sensitive||Neratinib||Phase II||Actionable||In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate of 3.8% (1/26), a clinical benefit rate of 42.3% (11/26), and a median progression-free survival of 5.5 months in patients with non-small cell lung cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926).||29420467|
|ERBB2 mutant||lung non-small cell carcinoma||sensitive||Neratinib||Phase I||Actionable||In a Phase I study, Nerlynx (neratinib) administered with temsirolimus was tolerable and demonstrated antitumor activity in ERBB2-mutant non-small-cell lung cancer (PMID: 24323026).||24323026|
|PubMed Id||Reference Title||Details|
|(24323026)||Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.||Full reference...|
|(29420467)||HER kinase inhibition in patients with HER2- and HER3-mutant cancers.||Full reference...|